OP-101

Orpheris enrolls first patients in phase 2 clinical study evaluating OP-101 for severe Covid-19
Pharmaceutical Business Review
Tue, 09/1/20 - 10:38 am
Orpheris
Ashvattha Therapeutics
OP-101
COVID-19
After passing safety hurdle, Orpheris kick-starts COVID-19 cytokine storm efficacy test
Fierce Biotech
Thu, 05/28/20 - 10:47 am
Orpheris
clinical trials
cytokine storm
COVID-19
OP-101